HomeCompareEVGGF vs ABBV

EVGGF vs ABBV: Dividend Comparison 2026

EVGGF yields 5.09% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 EVGGF wins by $6819.22M in total portfolio value
10 years
EVGGF
EVGGF
● Live price
5.09%
Share price
$61.45
Annual div
$3.13
5Y div CAGR
100%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$6819.33M
Annual income
$6,571,408,783.26
Full EVGGF calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — EVGGF vs ABBV

📍 EVGGF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodEVGGFABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, EVGGF + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
EVGGF pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

EVGGF
Annual income on $10K today (after 15% tax)
$432.82/yr
After 10yr DRIP, annual income (after tax)
$5,585,697,465.77/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, EVGGF beats the other by $5,585,676,409.77/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of EVGGF + ABBV for your $10,000?

EVGGF: 50%ABBV: 50%
100% ABBV50/50100% EVGGF
Portfolio after 10yr
$3409.71M
Annual income
$3,285,716,777.51/yr
Blended yield
96.36%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

EVGGF
Analyst Ratings
1
Hold
Consensus: Hold
Altman Z
6.1
Piotroski
5/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

EVGGF buys
0
ABBV buys
0
No recent congressional trades found for EVGGF or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricEVGGFABBV
Forward yield5.09%3.06%
Annual dividend / share$3.13$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR100%40.6%
Portfolio after 10y$6819.33M$102.3K
Annual income after 10y$6,571,408,783.26$24,771.77
Total dividends collected$6801.96M$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusHoldBuy

Year-by-year: EVGGF vs ABBV ($10,000, DRIP)

YearEVGGF PortfolioEVGGF Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$11,718$1,018.40$11,550$430.00+$168.00EVGGF
2$14,769$2,230.66$13,472$627.96+$1.3KEVGGF
3$21,058$5,255.01$15,906$926.08+$5.2KEVGGF
4$36,537$14,004.88$19,071$1,382.55+$17.5KEVGGF
5$84,514$45,419.16$23,302$2,095.81+$61.2KEVGGF
6$286,802$196,371.64$29,150$3,237.93+$257.7KEVGGF
7$1,552,476$1,245,598.67$37,536$5,121.41+$1.51MEVGGF
8$14,263,973$12,602,823.08$50,079$8,338.38+$14.21MEVGGF
9$231,698,486$216,436,035.44$69,753$14,065.80+$231.63MEVGGF
10$6,819,326,164$6,571,408,783.26$102,337$24,771.77+$6819.22MEVGGF

EVGGF vs ABBV: Complete Analysis 2026

EVGGFStock

Evolution AB (publ) develops, produces, markets, and licenses live casino and slots solutions to gaming operators primarily in Europe and the United States. The company runs the game from a casino gaming table, which is streamed in real time and end users make betting decisions on their devices, such as computers, smartphones, tablets, etc. Its portfolio of online live table games primarily includes Live Roulette, Blackjack, Baccarat, Super Sic Bo, Dragon Tiger, Craps, Live Casino Hold'em, Three Card Poker, and Ultimate Texas Hold'em; and operates approximately 1000 tables. The company was formerly known as Evolution Gaming Group AB (publ). Evolution AB (publ) was founded in 2006 and is headquartered in Stockholm, Sweden.

Full EVGGF Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this EVGGF vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

EVGGF vs SCHDEVGGF vs JEPIEVGGF vs OEVGGF vs KOEVGGF vs MAINEVGGF vs JNJEVGGF vs MRKEVGGF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.